September 2024 - Page 12 of 13

Dr. Jing Sun: SYK Inhibitors Set Sail at EHA – Solepinib’s Dual Mechanism Offers New Hope for ITP Treatment

By Mourabit Halima 2024.09.05

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.

Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

By Mourabit Halima 2024.09.05

Portal hypertension is a severe complication of chronic liver disease, directly associated with clinical outcomes such as ascites and variceal bleeding. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment that significantly reduces portal pressure. Portal pressure gradient (PPG) is commonly used to assess portal pressure in patients undergoing TIPS. Recently, a study led by Dr. Guohong Han's team from Xi'an International Medical Center Hospital, published in the Journal of Hepatology, explored the optimal timing and hemodynamic target for measuring PPG in cirrhotic patients with variceal bleeding after undergoing TIPS with covered stents.

Interventional Therapy in Hepatobiliary Diseases | Dr. Xuefeng Luo: In-depth Analysis of the French Guidelines on Transjugular Intrahepatic Portosyste

By Mourabit Halima 2024.09.04

Interventional therapy is an emerging clinical discipline and an important part of minimally invasive medicine. It stands as the third major clinical discipline, distinct from traditional internal medicine and surgery. Interventional therapy allows the treatment of various diseases through tiny channels a few millimeters in diameter created in the skin, using advanced imaging technologies such as DSA, ultrasound, and CT, without the need for large incisions to expose the lesion. Special needles, catheters, drugs, or stents are employed to treat the affected organs and tissues. To provide cutting-edge advancements in interventional hepatology, Hepatology Digest has partnered with Dr. Xuefeng Luo from West China Hospital of Sichuan University to create the "Interventional Therapy in Hepatobiliary Diseases" column. This monthly column aims to share the latest research, convey standardized treatment concepts, and track the latest developments in interventional therapy, with the goal of benefiting experts, researchers, and frontline medical workers in the field.

Dynamic Changes in Circulating Tumor DNA in Hepatocellular Carcinoma Patients Reveal Its Potential as a Non-Invasive Biomarker

By Mourabit Halima 2024.09.04

A recent clinical study conducted by Dr. Jean-Charles Nault and his team at the Cordeliers Research Center of Sorbonne University, France, was published in Gut journal. This study reveals the dynamic changes in circulating tumor DNA (ctDNA) in patients with hepatocellular carcinoma (HCC) and its clinical significance. The findings provide new perspectives and tools for the clinical management of HCC, highlighting the potential of ctDNA monitoring as an important adjunct in the diagnosis and treatment of HCC.

Newly Released! IDSA 2024 Guidelines for Treating Resistant Gram-Negative Bacterial Infections

By Mourabit Halima 2024.09.04

As antimicrobial resistance (AMR) continues to be a growing global public health challenge, treating infections caused by resistant bacteria has become increasingly difficult. Recently, the Infectious Diseases Society of America (IDSA) released the "IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections," providing clinicians with valuable treatment recommendations. This document primarily addresses infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E), AmpC beta-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia, offering specific and comprehensive treatment advice. Infectious Disease Frontier has translated and summarized the relevant recommendations from the document for reference by our readers.

Dr. Steven Narod: Bilateral Mastectomy and Breast Cancer Mortality—A Rethink of Clinical Guidelines

By Mourabit Halima 2024.09.04

In recent years, bilateral mastectomy, as a surgical approach to prevent contralateral breast cancer, has gained a certain degree of attention and application. However, there is still controversy regarding the actual effectiveness of bilateral mastectomy in preventing breast cancer mortality. Recently, Dr. Steven Narod from the Dalla Lana School of Public Health published a research paper titled "Bilateral Mastectomy and Breast Cancer Mortality" in JAMA Oncology. "Oncology Frontier" specially invited Dr. Steven Narod to share his latest research findings, hoping to provide more thoughts and guidance for the prevention, diagnosis, and treatment of breast cancer.

International Perspective丨Weighing the Risks of Chemotherapy: Is Chemotherapy Necessary for Adjuvant and Stage IV NSCLC Treatment?

By Mourabit Halima 2024.09.03

The necessity of adding chemotherapy to postoperative adjuvant treatment and in Stage IV non-small cell lung cancer (NSCLC) remains a topic of debate. In this article, Dr. Mark G. Kris from Memorial Sloan Kettering Cancer Center analyzes the value of chemotherapy in the adjuvant treatment of early-stage NSCLC with EGFR and ALK mutations, as well as in the treatment of advanced lung cancer.

International Perspective丨What Challenges Does Immunotherapy Face in Early-Stage NSCLC?

By Mourabit Halima 2024.09.03

The successes of immunotherapy and targeted therapy in metastatic non-small cell lung cancer (NSCLC) have raised hopes for implementing these therapies in earlier stages of the disease. Recent trial results indicate that neoadjuvant, adjuvant, and perioperative immunotherapy may improve the cure rates of early-stage NSCLC. While early diagnosis of patients could make immunotherapy a significant option for early-stage NSCLC, identifying reliable biomarkers remains a challenge.

Lung Cancer Frontline丨Dr. Cho Discusses the Impact of the CHRYSALIS-2 Cohort C Study on the Treatment of Atypical EGFR-Mutant Lung Cancer

By Mourabit Halima 2024.09.03

The CHRYSALIS-2 study (NCT04077463) Cohort C investigated the combination of amivantamab and lazertinib for the treatment of patients with atypical EGFR-mutant non-small cell lung cancer (NSCLC). The study enrolled patients with various EGFR mutations who were either treatment-naive or had received limited prior treatment. The results demonstrated that the amivantamab+lazertinib combination showed promising antitumor activity, particularly in treatment-naive patients. The overall response rate was 51% (95% CI: 41%-61%), with a response rate of 55% (95% CI: 40%-69%) in treatment-naive patients. In this subgroup, the median progression-free survival (PFS) for the amivantamab+lazertinib combination was 19.5 months (95% CI: 11.0-not estimable). Overall, these findings suggest that amivantamab+lazertinib has potential as a new treatment option for patients with advanced NSCLC carrying atypical EGFR mutations. Principal investigator Dr. Byoung Chul Cho from Yonsei Cancer Center in Korea discussed the results of this study in an international media interview.

International Lung Cancer Academic Conference | Dr. Chunxue Bai: Lung Cancer Screening and Management in the Metaverse Era

By Mourabit Halima 2024.09.03

In 2022, Dr. Chunxue Bai from Fudan University Shanghai Cancer Center, introduced the concept of "Metaverse Medicine," aiming to leverage metaverse technology to revolutionize disease prevention and treatment. At the 2024 International Lung Cancer Academic Conference, Professor Bai presented a report titled "Lung Cancer Screening and Management in the Metaverse Era." This article provides a summary of the main points of his report.